AI Article Synopsis
- TDO2 is expressed at higher levels than IDO1 in triple-negative breast cancer (TNBC).
- Knocking down TDO2 can trigger an increase in IDO1 as a compensatory response.
- A new dual inhibitor targeting both TDO2 and IDO1 reduces tryptophan catabolism, inhibits anchorage-independent survival, and decreases invasive capabilities of cancer cells.
Article Abstract
TDO2 is more highly expressed than the nonhomologous TRP-catabolizing enzyme IDO1 in TNBC. We find that TDO2 knockdown can lead to a compensatory increase in IDO1. Therefore, we tested a newly developed TDO2/IDO1 dual inhibitor and found that it decreases TRP catabolism, anchorage-independent survival, and invasive capacity.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11484926 | PMC |
| http://dx.doi.org/10.1158/2767-9764.CRC-24-0272 | DOI Listing |
Publication Analysis
Top Keywords
invasive capacity
8
blocking tryptophan
4
tryptophan catabolism
4
catabolism reduces
4
reduces triple-negative
4
triple-negative breast
4
breast cancer
4
cancer invasive
4
capacity tdo2
4
tdo2 highly
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!